Our advisory council is made up of leading multidisciplinary experts in spinal cord injury R&D. At the frontline of academic research, they inform our strategy with the latest findings.
Investment strategy
An early-stage fund with deep sector expertise
Catalyzing an investment market to address spinal cord repair.
Recent advances in science and technology have made recovery from paralysis a real possibility.
We target near-term functional improvement, while also backing the ultimate goal of biological repair of the spinal cord. Our strategy is guided by the priorities of those living with a spinal cord injury. We focus on curative therapies for motor and sensory deficits and leave the important work of care and adaptation to others.
SCI Ventures is uniquely positioned to de-risk assets for a broad range of adjacent neurological conditions.
We invest in technologies targeted at SCI. There are many similarities between SCI and other conditions including stroke, neurodegenerative diseases or neural circuit disorders such as epilepsy or pain. The technologies we back have the potential to yield high impact beyond the SCI community.
We use strict criteria to assess a company’s investment impact, focusing on prospective financial return.
We aim to make an impact, by identifying the most innovative technologies and supporting at an early stage the most entrepreneurial management teams, regardless of where they are in the world. We assess each company for its scientific maturity and potential for clinical impact.
Clinical impact
Scientific maturity
Commercially attractive
Collaborative expertise and decision-making
Our Investment Committee makes portfolio decisions after drawing upon the expertise of our Scientific Advisory Committee. Both committees include representatives from the research foundations who support us and we foster frequent collaboration throughout the international SCI ecosystem.
We bring to the table not just funding, but access to a rich network that spans:
Discovery science
Standardized pre-clinical models
Rehabilitation
Patient advocacy
Scientific Advisory Board
Our mission is guided by scientific rigor
Murray Blackmore, PhD
Professor Marquette University
Leader in nerve regeneration & genetic control
Rob Brownstone, MD, PhD
Professor of Neurosurgery, Brain Research UK
Head of the Division of Neurosurgery UCL
Edelle Field-Fote, PhD
Director, Spinal Cord Injury Research, Shepherd Center
Professor, Emory University School of Medicine, Division of Physical Therapy
Professor of the Practice, Georgia Institute of Technology, School of Biological Sciences
Phil Horner, PhD
Professor of Neuroregeneration
Director, Center for Neuroregeneration at Houston Methodist
Chet Moritz, PhD
Professor of Electrical & Computer Engineering, University of Washington,
Co-Director, Center for Neurotechnology
Armin Curt, MD, PhD
Professor for Paraplegiology, University of Zurich,
Chief and Director Spinal Cord Injury Center